This bill removes criminal liability for New Jersey law enforcement officers who interact with underage individuals regarding alcohol or cannabis possession, unless the officer intentionally discriminates based on race, gender, religion, or other protected characteristics. Currently, officers face criminal charges for such encounters regardless of intent, but this bill changes that by requiring proof of discriminatory purpose to trigger liability. Key provisions clarify that officers cannot be charged for routine actions like issuing warnings or conducting stops without reasonable suspicion - unless they act with discriminatory intent. The change directly affects officers responding to underage possession calls and the young people involved in these encounters.
This bill creates a new criminal offense for marketing fentanyl in ways specifically designed to appeal to minors, targeting manufacturers, distributors, or sellers. It prohibits tactics like packaging resembling candy, food, or popular characters, using minor-targeted advertising, or violating FDA/DEA packaging rules. Violators face a minimum 30-year prison sentence with no parole eligibility, and prior fentanyl distribution convictions create a strong presumption of guilt. The law directly affects businesses or individuals distributing fentanyl with marketing strategies targeting youth, aiming to deter such practices through severe penalties.
This New Jersey bill (A 864) classifies xylazine - a sedative often misused in illicit drug mixtures - as a Schedule III controlled substance under state law, except when used by veterinarians for animal treatment. Schedule III means it has accepted medical use but potential for abuse leading to moderate dependence, subjecting unauthorized use to criminal penalties. Specifically, illegal possession, distribution, or use of xylazine would be a third-degree crime, punishable by 3-5 years in prison and fines up to $35,000, with enhanced penalties near schools or for distributing to minors. The bill directly affects individuals misusing xylazine (including in human drug use) and law enforcement, while exempting veterinary medical use.
New Jersey's A 2136 creates new criminal penalties for unlicensed marijuana sales and purchases. It makes it a third-degree crime (up to 5 years in prison or $15,000 fine) for owners of unlicensed businesses that manufacture, distribute, or dispense marijuana, and a second-degree crime (up to 10 years or $150,000 fine) for leaders of multi-location illegal networks. The bill also imposes a misdemeanor charge (up to 6 months or $1,000 fine) for knowingly buying marijuana from unlicensed businesses. Enforcement allows state police and the Attorney General to shut down violating businesses and seize illegally sold marijuana. This bill supplements existing law (CREAMMA) by adding specific penalties for unlicensed commercial activity, not personal use.
This bill establishes a 500-foot drug-free zone around licensed child care centers in New Jersey, prohibiting the distribution, possession, or dispensing of controlled dangerous substances within that area. It directly affects individuals who sell or distribute drugs near these centers, with violations classified as a third-degree crime carrying mandatory minimum prison terms (one-third to one-half of the sentence, or one year for small marijuana amounts, or three years for other drugs). Key provisions require courts to impose parole ineligibility during these minimum terms, though judges may reduce penalties if children weren't present, violence wasn't involved, or the offense occurred outside school hours. The law also includes an affirmative defense for offenses entirely within private residences with no minors present and no profit motive. The bill is currently pending before the Assembly Children, Families and Food Security Committee.
S 2271, "CJ's Law," amends New Jersey's controlled substances law to criminalize the manufacture and distribution of substances containing kratom under specific circumstances. This bill directly affects kratom businesses, distributors, and retailers by making these activities illegal under state law. The key mechanism adds kratom to the definition of "controlled dangerous substances" in N.J.S. 2C:35-2, treating it like other illegal drugs, while explicitly excluding hemp and cannabis products regulated under separate state laws. The law does not change existing legal status for hemp or cannabis products under the New Jersey Hemp Farming Act or Cannabis Regulatory Act.
This bill creates new criminal penalties for selling or buying marijuana from unlicensed businesses in New Jersey. It makes it a third-degree crime (up to 5 years in prison or $15,000 fine) for unlicensed business owners to manufacture, distribute, or dispense marijuana, and a second-degree crime (up to 10 years or $150,000 fine) for leaders of multi-location illegal networks. Purchasing from unlicensed sources becomes a disorderly persons offense (up to 6 months jail or $1,000 fine). The New Jersey State Police can shut down violating businesses and seize illegal marijuana.
S 829, titled "CJ's Law," would make it illegal to manufacture, sell, or possess substances containing kratom in New Jersey. The bill amends state drug laws to explicitly include kratom under prohibited "controlled dangerous substances," creating new criminal penalties for these activities. This change would directly affect individuals who use or sell kratom products, as current law does not ban kratom. The law would apply to all kratom-containing substances, including those sold as dietary supplements or recreational products.
New Jersey's S 1865 adds seven specific illicit fentanyl analogs - Furanyl Fentanyl, 3-Methylfentanyl, 3-Methyl Butyrylfentanyl, Valeryl Fentanyl, Norfentanyl, Para-Fluorobutyryl-Fentanyl, and Carfentanyl - to Schedule I of the state's Controlled Dangerous Substances Act. This formalizes their current administrative classification (already in effect since 2017), meaning these substances are now legally treated as having high abuse potential with no accepted medical use. The bill directly affects law enforcement, healthcare providers, and individuals handling these compounds, requiring strict regulatory controls. Prescription fentanyl remains classified separately as a Schedule II substance.
Bill S 103 creates new criminal offenses for the unlawful possession and use of credit card scanners in New Jersey. It makes possessing such a device without a lawful purpose a disorderly persons offense (misdemeanor punishable by up to $1,000 fine or 6 months in jail), and using it for unlawful purposes a second-degree crime (felony punishable by up to $150,000 fine or 5-10 years in prison). The bill directly affects individuals who handle credit card scanners without authorization, such as those attempting to steal card data. Key provisions define "credit card scanner" broadly as any device that reads, records, or transmits card information, and establish specific penalties for each violation. The law takes effect two months after enactment.
